Highlights include an oral presentation of a subset analysis from the Phase 3 clinical trial of zoliflodacin, an investigational single-dose oral treatment for uncomplicated gonorrhea due to Neisseria gonorrhoeae WALTHAM, Mass. / Oct 07, 2025 / Business Wire / Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced that it will deliver data from six presentations at IDWeek 2025,... Read More

BURLINGAME, Calif. / Aug 26, 2025 / Business Wire / Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor... Read More

WALTHAM, Mass. / Aug 13, 2025 / Business Wire / Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc . (NASDAQ: INVA), announced today that two of the company’s infectious disease therapies, ZEVTERA ® (ceftobiprole medocaril sodium for injection) and XACDURO ® (sulbactam/durlobactam for injection) have been nominated for the prestigious 2025 Prix Galien USA Award, “ Best Pharmaceutical Product.” "We are honored... Read More

Strong royalties portfolio performance with $67.3 million in revenue IST achieved U.S. net product sales of $29.0 million, reflecting 54% year-over-year growth ZEVTERA (ceftobiprole medocaril sodium, for injection) launched in the U.S. Zoliflodacin NDA accepted by FDA with Priority Review; PDUFA date set for December 15, 2025 BURLINGAME, Calif. / Aug 06, 2025 / Business Wire / Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the... Read More

FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letter If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades WALTHAM, Mass. & GENEVA / Jun 12, 2025 / Business Wire / Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic... Read More

In laboratory studies, zoliflodacin has been shown to be active against Neisseria gonorrhoeae including multidrug-resistant strains. If approved, zoliflodacin could become the first new antibiotic treatment for gonorrhea in decades. WALTHAM, Mass. & GENEVA, Switzerland / Jun 10, 2025 / Business Wire / Innoviva Specialty Therapeutics, Inc. , a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global... Read More

BURLINGAME, Calif. / Jun 03, 2025 / Business Wire / Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor... Read More

ZEVTERA is the first and only U.S. Food and Drug Administration-approved cephalosporin indicated to treat Staphylococcus aureus bacteremia (SAB), including right-sided endocarditis, caused by the methicillin-resistant Staphylococcus aureus (MRSA). WALTHAM, Mass. / May 20, 2025 / Business Wire / Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced the United States commercial... Read More

Core royalty platform maintained strong performance, generating $61.3 million in revenue Innoviva Specialty Therapeutics achieved U.S. net product sales of $26.4 million for the first quarter, reflecting 52% year-over-year growth Continued momentum across therapeutics platform with regulatory submissions for zoliflodacin and commercial launch of ZEVTERA ® (ceftobiprole) progressing as planned BURLINGAME, Calif. / May 07,... Read More

BURLINGAME, Calif. / Mar 05, 2025 / Business Wire / Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a... Read More

Core royalty platform continues to deliver with GSK royalties of $66.0 million for the fourth quarter and $255.6 million for the full year Innoviva Specialty Therapeutics achieved U.S. net product sales of $24.9 million for the fourth quarter and $80.9 million for the full year, reflecting 47% year-over-year growth Therapeutics platform strengthened with acquisition of exclusive U.S. commercialization and distribution rights... Read More

BURLINGAME, Calif. / Feb 06, 2025 / Business Wire / Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a... Read More

BURLINGAME, Calif. / Dec 16, 2024 / Business Wire / Innoviva Specialty Therapeutics, Inc ., (“IST”) a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced it has entered into an exclusive distribution and license agreement with Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), for the commercialization of Zevtera ® (ceftobiprole), an advanced-generation cephalosporin antibiotic, in the United States. "The licensing... Read More

BURLINGAME, Calif. / Nov 26, 2024 / Business Wire / Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a... Read More

BURLINGAME, Calif. / Nov 12, 2024 / Business Wire / Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in a fireside chat at the UBS... Read More

Core royalty platform continued strong performance, receiving GSK royalties of $60.5 million with 6% year-over-year growth Innoviva Specialty Therapeutics’ (IST) marketed portfolio achieved U.S. net product sales of $19.7 million, reflecting 68% year-over-year growth BURLINGAME, Calif. / Nov 06, 2024 / Business Wire / Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core... Read More

BURLINGAME, Calif. / Sep 04, 2024 / Business Wire / Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor... Read More

Core royalty platform continued strong performance, receiving GSK royalties of $67.2 million Innoviva Specialty Therapeutics’ (IST) marketed portfolio grew 38% year-over-year, achieving net product sales of $21.7 million Important treatment guidelines and guidance updates recognized our key products: XACDURO ® by 2024 Infectious Diseases Society of America (IDSA); XERAVA ® by 2024 Surgical Infection Society XACDURO ®... Read More

BURLINGAME, Calif. / Jun 03, 2024 / Business Wire / Innoviva, Inc. (Nasdaq: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a... Read More

Core royalty platform on track; receiving GSK royalties of $61.9 million Achieved net product revenues of $19.1 million, representing 66% year-over-year growth driven by launch of XACDURO® and growth of key core product GIAPREZA® Strong pipeline progress: positive Phase 3 zoliflodacin clinical trial results in uncomplicated gonorrhea highlighted at ESCMID Global 2024; on track to submit NDA in early 2025 Derek Small... Read More

BURLINGAME, Calif. / May 08, 2024 / Business Wire / Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will present at the... Read More

Single-dose, oral zoliflodacin achieved 90.9% microbiological cure rate, demonstrating statistical non-inferiority compared to current global standard of care Pivotal Phase 3 data to be presented by the Global Antibiotic Research & Development Partnership (GARDP) in a Scientific Sessions Oral Presentation First collaborative study between industry and a non-profit to address a World Health Organization high priority pathogen... Read More

Core royalty platform on track; received GSK royalties of $69.6 million for fourth quarter Achieved net product revenues of $19.7 million for the fourth quarter of 2023 representing 35% year on year growth Strong pipeline progress in 2023: Approval and launch of first pathogen targeted antibacterial XACDURO® for treatment of HABP/VABP caused by Acinetobacter infections; positive topline Phase 3 data for oral drug... Read More

Received GSK royalties of $57.0 million and net product revenues of $13.7 million in the third quarter of 2023 Launched first-in-class therapy XACDURO ® for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter Announced positive topline Phase 3 zoliflodacin data for treatment of gonorrhea in November 2023 Repurchased $11.0 million of... Read More

A Phase 3 study of oral zoliflodacin met the primary endpoint when compared against the combination of injectable ceftriaxone and oral azithromycin, a current international standard of care. Positive top-line study results are a significant milestone in the development of a first-in-class antibiotic against drug-resistant Neisseria gonorrhoeae, a high priority pathogen . Groundbreaking antibiotic research and development... Read More

BURLINGAME, Calif. / Sep 19, 2023 / Business Wire / Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Cantor Global Healthcare Conference in New York, NY on Wednesday, September 27, 2023 at 1:50 p.m. Eastern Time. A live webcast of the... Read More

XACDURO is a new FDA-approved treatment used to fight against HABP/VABP infections caused by isolates of Acinetobacter baumannii-calcoaceticus complex, which can include those resistant to carbapenems (CRAB). In the U.S., it is estimated there are more than 40,000 cases of Acinetobacter each year and approximately 40 percent are carbapenem-resistant. 1,2 Patients with HABP/VABP caused by Acinetobacter infections face high... Read More

BURLINGAME, Calif. / Aug 25, 2023 / Business Wire / Innoviva, Inc. ( NASDAQ: INVA) (“Innoviva” and “the Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced the appointment of Stephen Basso as its Chief Financial Officer, effective August 21, 2023. “We are excited to welcome Stephen to our executive leadership team and believe the Company will benefit greatly... Read More

Received GSK royalties of $65.7 million, net product revenues of $15.7 million and license revenue of $3.0 million in the second quarter of 2023 Received FDA approval for XACDURO® for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter Repurchased $9.2 million of common stock BURLINGAME, Calif. / Aug 02, 2023 / Business Wire /... Read More

BURLINGAME, Calif. / Jun 06, 2023 / Business Wire / Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will present at the Goldman Sachs Annual Global Healthcare Conference in Dana Point, CA on Monday, June 12 th , 2023 at 2:00 p.m. Pacific Time. The presentation will be webcast and... Read More

Indicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter First pathogen-targeted therapy addressing Acinetobacter, including resistant strains, an emerging global health threat and growing unmet need WALTHAM, Mass. / May 23, 2023 / Business Wire / Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq:... Read More

Sulbactam-durlobactam is the first pathogen-targeted therapy under investigation for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter). WALTHAM, Mass. / May 11, 2023 / Business Wire / Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA) focused on... Read More

Received GSK royalties of $60.3 million, net product revenues of $11.5 million and license revenue of $8.0 million in the first quarter of 2023 Repurchased $40.3 million of common stock and paid off $96.2 million of 2023 convertible notes BURLINGAME, Calif. / May 09, 2023 / Business Wire / Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or “the Company”), a diversified holding company with a portfolio of royalties and other... Read More

BURLINGAME, Calif. / Apr 28, 2023 / Business Wire / Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) and George Bickerstaff, III, Chairman of the Board of Directors of the Company (the “Board”) today announced that Mr. Bickerstaff would not stand for reelection at the Company’s 2023 Annual Meeting. Following the Meeting, assuming that all other members of the Board are reelected, the Board will be comprised of... Read More

New Drug Application (NDA) for sulbactam-durlobactam for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter), is currently under Priority Review by the FDA with a PDUFA target action date of May 29, 2023 BURLINGAME, Calif. / Apr 17, 2023 / Business Wire / Innoviva, Inc.... Read More

FDA Advisory Committee to review sulbactam-durlobactam for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter BURLINGAME, Calif. / Apr 17, 2023 / Business Wire / Innoviva, Inc. (Nasdaq: INVA) (Innoviva), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that Nasdaq has halted trading of... Read More

BURLINGAME, Calif. / Mar 13, 2023 / Business Wire / Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee will convene April 17, 2023 to review data supporting the new drug application (NDA) for sulbactam-durlobactam (SUL-DUR). SUL-DUR is an... Read More

BURLINGAME, Calif. / Feb 28, 2023 / Business Wire / Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or “the Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the fourth quarter ended December 31, 2022. Gross royalty revenues of $54.7 million from Glaxo Group Limited (“GSK”) for the fourth quarter of 2022 included royalties of $44.3 million from... Read More